The myotonic dystrophies [DM], including myotonic dystrophy type 1 [DM 1] and myotonic dystrophy type 2 [DM2], are dominantly inherited, multisystem diseases that share the major disease manifestations of myotonia, wasting ad weakness. DM1 is caused by an unstable CTG repeat expansion on chromosome 19q13.3 and DM2 by an unstable CCTG repeat expansion 3q21. The cause for the skeletal muscle findings in these disorders remains a mystery. We hypothesize that they result from toxic effect of mutant RNA, a RNA mediated gain of function. Support for our hypothesis comes from studies in a mouse model of DM1. The muscles of the mice show a focal accumulation of expanded CUG repeats in the nucleus. These nuclear foci closely resemble the RNA foci of expanded CUG repeats in DM1 and expanded CCUG repeats in DM2. Expression of the expanded CUG repeat in the transgenic model causes myotonia, like that seen in DM1 and DM2. We have obtained evidence that myotonia in the transgenic model results from aberrant splicing of the chloride channel 1(CIC-1) pre-mRNA, and consequent loss of CIC-1 protein and chloride conductance from the muscle membrane. We hypothesize that a similar RNA-mediated disturbance of RNA processing underlines myotonia and other disease manifestations in DM1. To test this hypothesis we will evaluate patients with DM1 and DM2, disease controls, and normals using clinical and electromyographic testing, needle muscle biopsy, tissue culture techniques, studies of RNA expression and splicing, immunofluorescence microscopy, and microarray analysis to address four specific aims.
These aims are: 1) define the mechanism of myotonia - analyze splicing of CIC1 inDM1 and DM2; 2) determine the extent of mis-splicing (beyond CIC1) in DM1 and DM2; 3) examine the structure/distribution/protein binding characteristics of the nuclear foci containing the expanded repeats in DM1 and DM2; and, 4) assess the expression profile of mRNA inDM1 and DM2. The results of these investigations will shed light on the possibility that RNA gain-of-function represents a fundamental, shared disease mechanism in all forms of myotonic dystrophy. The findings may also help to explain the common clinical manifestations that occur in DM1, DM2, and other myotonic dystrophy like disorders. Ultimately our results may improve our understanding of the pathophysiology of DM and guide us toward the development of new approaches to treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR049077-03
Application #
6780969
Study Section
Special Emphasis Panel (ZRG1-SMB (01))
Program Officer
Nuckolls, Glen H
Project Start
2002-08-01
Project End
2006-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
3
Fiscal Year
2004
Total Cost
$343,744
Indirect Cost
Name
University of Rochester
Department
Neurology
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Hoskins, Jason W; Ofori, Leslie O; Chen, Catherine Z et al. (2014) Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. Nucleic Acids Res 42:6591-602
Nakamori, Masayuki; Sobczak, Krzysztof; Puwanant, Araya et al. (2013) Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol 74:862-72
Childs-Disney, Jessica L; Stepniak-Konieczna, Ewa; Tran, Tuan et al. (2013) Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat Commun 4:2044
Sobczak, Krzysztof; Wheeler, Thurman M; Wang, Wenli et al. (2013) RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy. Mol Ther 21:380-7
Childs-Disney, Jessica L; Parkesh, Raman; Nakamori, Masayuki et al. (2012) Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1. ACS Chem Biol 7:1984-93
Ofori, Leslie O; Hoskins, Jason; Nakamori, Masayuki et al. (2012) From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy. Nucleic Acids Res 40:6380-90
Chen, Catherine Z; Sobczak, Krzysztof; Hoskins, Jason et al. (2012) Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1. Anal Bioanal Chem 402:1889-98
Parkesh, Raman; Childs-Disney, Jessica L; Nakamori, Masayuki et al. (2012) Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J Am Chem Soc 134:4731-42
Tang, Zhen Zhi; Yarotskyy, Viktor; Wei, Lan et al. (2012) Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel. Hum Mol Genet 21:1312-24
Childs-Disney, Jessica L; Hoskins, Jason; Rzuczek, Suzanne G et al. (2012) Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem Biol 7:856-62

Showing the most recent 10 out of 30 publications